What: Shares of Array BioPharma, a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from ...

NEW YORK (AP) — Pfizer is buying the cancer treatment company Array BioPharma in a deal worth $11.4 billion. Array has a combination therapy for BRAF-mutant metastatic melanoma, along with a pipeline ...

Array BioPharma Inc. of Boulder, Colo., and Celgene Corporation, a Summit-based biopharmaceutical company, have announced a research and development collaboration on the discovery, development and ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

What: Shares of Array BioPharma, a biopharmaceutical company that's focused on developing novel drugs to fight cancer, skyrocketed by 51% in January, based on data from S&P Capital IQ, after ...

Boulder’s Array BioPharma Inc. is merging with Pfizer Inc. in an $11.4 billion deal. The merger agreement was announced Monday. Array BioPharma is a commercial stage biopharmaceutical company focused ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

After reporting fiscal second-quarter financials that were better than hoped, Array BioPharma (NASDAQ: ARRY) saw its shares surge 11.3% as of 3:40 p.m. EST on Tuesday. Array BioPharma has said in the ...

Pfizer (PFE-3.82%) is at it again. After a couple of years without any significant merger and acquisition activity, the big drugmaker announced on Monday that it's buying Array BioPharma (ARRY). The ...

Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...

In response to the company posting good-looking fiscal 2019 first-quarter results, shares of Array BioPharma (NASDAQ: ARRY) , a commercial-stage biopharma focused on cancer, rose as much as 10% in ...